ENSC Ensysce Biosciences Inc. Aggregate Debt Obligations

Ensysce Biosciences (ENSC) develops abuse-deterrent analgesics through partnerships with medical centers, which increases the likelihood of an acquisition. The company's price chart on GURU.Markets based on the separate_debt metric is 0.00. A stable raw material reserve and flexible supply routes ensure operational continuity. Proprietary formulas provide high growth potential, enabling low-cost drug production for the global market following certification.

Ensysce Biosciences - ENSC Company Debts (period 07/04/2022 - 10/27/2026)

ENSC (Ensysce Biosciences): analytical breakdowns and indicator data

- price and consensus price forecast:

Stock Price ensysce.com|ENSC - Price Target Chart

- market capitalization data:

Market Value Ensysce|ENSC - Enterprise Value

- book capitalization data:

Accounting Value per Share Ensysce Biosciences|ENSC - Company Book Value|Market-to-Book Ratio ensysce.com|ENSC - Cumulative Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Ensysce Biosciences|ENSC - Long-Term Debt to Capital|Current Liabilities to Equity ensysce.com|ENSC - Company Aggregate Debts|Debts to Book Capitalization Ensysce

General company analysis:Ensysce Biosciences Inc. ENSC

Signature product of Ensysce Biosciences

The development of Ensysce Biosciences (ENSC) proprietary TAAP and MPAR platforms requires significant R&D investment to maintain a technological edge in the opioid protection sector. GURU.Markets analytics tracks operational changes in total borrowed capital via the debt load trajectory, allowing investors to assess the balance between the cost of capital and the risk of liquidity loss amid a volatile borrowing market.

Main competitors